Clients News • MC Services corporate website
5522
paged,page-template-default,page,page-id-5522,paged-2,page-paged-2,bridge-core-2.1.4,qode-listing-1.0.1,qode-social-login-1.0,qode-quick-links-1.0,ajax_fade,page_not_loaded,,qode-title-hidden,paspartu_enabled,qode_grid_1400,footer_responsive_adv,qode-content-sidebar-responsive,qode-child-theme-ver-1.0.0,qode-theme-ver-20.1,qode-theme-bridge,disabled_footer_top,qode_header_in_grid,bridge-child,wpb-js-composer js-comp-ver-6.4.2,vc_responsive

CLIENT NEWS

 

 

  • AiCuris to Present at the 39th Annual J.P. Morgan Healthcare Conference
    www.aicuris.com
  • CEVEC announces new license agreement for its AAV manufacturing technology ELEVECTA(R) in gene therapy
    www.cevec.com
  • sterna biologicals GmbH & Co. KG raises further EUR 10.0 million (approx. USD 11.9 million) in Series A – 2nd closing private placement
    www.sterna-biologicals.com
  • RedHill Biopharma’s RHB-204 Granted FDA Fast Track Designation for NTM Disease
    www.redhillbio.com
  • Atriva Therapeutics obtains approval from German authorities for Phase II trial in COVID-19 patients, led by Charité Clinic in Berlin
    www.atriva-therapeutics.com
  • Abivax Publishes Review in Drug Discovery Today on Mechanism of Action and Transformative Potential of ABX464 as Therapy for Inflammatory Diseases
    www.abivax.com
  • ViGeneron signs global collaboration agreement for ophthalmic gene therapy development
    www.vigeneron.com
  • Adrenomed AG: Adrenomed Supervisory Board appoints Dr. Wolfgang Baiker as CEO
    www.andrenomed.com
  • RedHill Biopharma Announces Positive Top-Line Safety and Efficacy Data from Phase 2 COVID-19 Study of Opaganib
    www.redhillbio.com
  • 4basebio AG announces changes to the Management Board
    www.4basebio.com